InvestorsHub Logo
icon url

jessellivermore

10/29/13 8:59 AM

#19502 RE: bobjones2731 #19501

Dear bobjones..

It's only human that after the huge shock of the AdComm circus the CEO might be in shock...I know I was in shock. I have done a lot of research into AMRN's situation, and I could not answer the question if there has ever been a case where the FDA reneged on an SPA..And at the time the questioned was raised, there was no one on this board that knew the answer.

I have invested in a lot of biotechs..It is not a game for sissies. When the FDA dings the company or the trial fails it is always the head of the CEO the mob wants. Dealing with the FDA requires the skill of a lion tamer. You have to keep the beast in sight at all times and try not to do anything that angers it. What more can the company, the CEO do except comply with the FDA's requests, the FDA admits AMRN has met its wishes..What else do you want the guy to do?..Seriously make a positive suggestion.

":>) JL

icon url

Dancing in the dark

10/29/13 9:03 AM

#19503 RE: bobjones2731 #19501

i believe what you heard in the responses during the conference call
was indicative of amarin sr. mgmt having not even considered the
notion that the ANCHOR SPA was somehow jeopardized by the AdCom outcome.

the analyst(s) asking the questions were jumping to conclusions
and asking for factual responses, responses amarin management had no
basis to have prepared.

when you prepare for a debate about risk/benefit of vascepa safety/efficacy
in lowering triglycerides and are instead met with discussion
about cardio protection data not yet resulted, you wonder
WTF is going on, but you cannot convey that wonderment to FDA or
amarin stakeholders in an unrehearsed conference call.
icon url

drrc1949

10/29/13 1:15 PM

#19519 RE: bobjones2731 #19501

bobjones2731, I just read your post. It seems that in fairness I should allow JZ a little space to maneuver (see my post #19515), but I really FEEL like responding to your post with one word......DITTO!!!